BioFluidica
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11575 Sorrento Valley Rd Ste 210, San Di...Phone Number
(858) 535-6493Website
www.biofluidica.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About BioFluidica
BioFluidica is a privately held biotechnology company that has developed a revolutionary platform enabling disease management and diagnosis through prognosis, all from a simple blood test. The BioFluidica microfluidic platform can capture and isolate disease biomarkers, such as Circulating Tumor Cells (CTC), and has been clinically validated. Its ability to scan whole blood for the first signs of a disease, finding the rarest biomarkers with unmatched sensitivity, means fulfilling the promise of a true liquid biopsy. BioFluidica is revolutionizing disease detection by bringing better samples to millions of people.Explore more
BioFluidica Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioFluidica your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once BioFluidica has new funding data
Click to see if BioFluidica had a recent Job posting/layoffs
Product Launch: Get notified when BioFluidica launches new products
Congratulate Masked Content for being promoted to Masked Content at BioFluidica
BioFluidica, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on BioFluidica recently announced quarterly report
Check if BioFluidica has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if BioFluidica is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined BioFluidica as Masked Content
Find 3 more new buyers
Compare Similar Companies to BioFluidica
Compare insights from companies similar to BioFluidica, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioFluidica is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BioFluidica is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BioFluidica.
BioFluidica financials insights
Gather financial insights about BioFluidica, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$2M
2017
Private Equity
$4.1M
2020
Debt
$150K
2021
Debt
$208K
2022
Series B
$6M
BioFluidica Tech Stack
A closer look at the technologies used by BioFluidica
Most Recent Scoops
Event
will be attending the 2022 AACC Annual Scientific Meeting + Clinical Lab Expo conference as an exhibitor. The event will occur from July 24 to July 28, 2022.
New Hire
Executive Move
Stephen Sharp has joined the organization as Director, Marketing & Product Management.
Executive Moves, New Hire
Funding
Funding
BioFluidica has received an SBA PPP loan in the amount of $208,988 from Silicon Valley Bank resulting in the retention of 9 jobs.
Funding
BioFluidica News & Media
BioFluidica Next-Generation Liquid Biopsy Platform Uncovers Undiagnosed HER2+ Patients
SAN DIEGO, June 24, 2022 /PRNewswire/ -- Biofluidica today announced the results of a breast cancer study comparing invasive needle biopsies with their non-invasive, highly sensitive Next-Generation Liquid Biopsy platform, LiquidScan™ to detect HER2 positive (HER2+) patients. Patients...BioFluidica to Introduce Next-Generation Biomarker Isolation Platform
LiquidScan™ at the 2022 American Association for Cancer Research Meeting in New Orleans BioFluidica LiquidScan Harnesses the Power of Microfluidics SAN DIEGO, April 5, 2022 /PRNewswire/ -- Biofluidica, Inc., a privately held biotechnology company, today announced they will be introducing...BioFluidica Extends NIH Award through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight Against COVID-19
BioFluidica LiquidScan Next-Generation Testing Platform, Can Detect Diseases in 15 Minutes SAN DIEGO, March 23, 2022 /PRNewswire/ -- BioFluidica, a privately held biotechnology company, today announced they have been awarded a continuation grant from the Midwest Biomedical Accelerator...BioFluidica Announces $6 Million Series B2 Funding to Support the Commercialization of its Liquid Biopsy Microfluidics Platform, the LiquidScan™, and the Development of its Advanced Handheld Covid-19 Detection Device for Consumer At-Home Testing
SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- BioFluidica, Inc., a biotechnology company developing a diagnostic platform allowing for disease management and diagnosis, today announced that it has raised over $6 million in the initial closings of its Series B2 financing. Additional closings in...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding BioFluidica
Sign Up For FreeTo access detailed company insights
BioFluidica is a privately held biotechnology company that has developed a revolutionary platform enabling disease management and diagnosis through prognosis, all from a simple blood test. The BioFluidica microfluidic platform can capture and isolate disease biomarkers, such as Circulating Tumor Cells (CTC), and has been clinically validated. Its a... Read More
